Suppr超能文献

慢性阻塞性肺疾病相关骨质疏松症:被低估的系统性因素。

Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component.

机构信息

Department of Respiratory Medicine, University Medical Centre Maastricht, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.

出版信息

Respir Med. 2009 Aug;103(8):1143-51. doi: 10.1016/j.rmed.2009.02.014.

Abstract

RATIONALE

Chronic obstructive pulmonary disease (COPD) patients are at increased risk of osteoporosis. Osteoporosis is under diagnosed and under treated in these patients and the underlying mechanisms remain unclear. To date, screening recommendations for osteoporosis in COPD patients are not available.

OBJECTIVES

To examine the prevalence of drug treatment of bone abnormalities as well as the clinical determinants of osteoporosis in COPD.

METHODS

COPD patients (n=554) consecutively entering pulmonary rehabilitation were included in this cross-sectional study. Medical history, current medication use, smoking status, lung function, bone mineral density, body composition and other clinical characteristics were assessed before entering pulmonary rehabilitation. Univariate- and multivariate multinomial logistic regression analyses were used to determine correlates of osteoporosis.

MAIN RESULTS

Twenty-one percent of patients had osteoporosis and 41% had osteopenia. Osteoporosis was pharmacologically under treated (82% of osteoporotic patients were not receiving bone medication). Independent predictors of osteoporosis were cachexia (OR: 12.1; 95%CI: 4.5-32.7; p<0.001), age between 55 and 65 years (OR: 6.0; 95%CI: 2.2-16.3; p<0.001) and over 65 years (OR: 11.7; 95%CI: 4.1-33.1; p=<0.001). Overweight (OR: 0.1; 95%CI: 0.05-0.4; p=0.001) and obesity (OR: 0.78; 95%CI: 0.02-0.4; p=0.002) showed a substantial protective effect.

CONCLUSIONS

The majority of COPD patients with osteoporosis entering pulmonary rehabilitation did not receive pharmacological treatment for osteoporosis. Cachectic COPD patients should be screened for osteoporosis, especially when over 55 years of age.

摘要

背景

慢性阻塞性肺疾病(COPD)患者骨质疏松的风险增加。这些患者中骨质疏松症的诊断和治疗不足,其潜在机制尚不清楚。迄今为止,COPD 患者骨质疏松症的筛查建议尚不可用。

目的

检查 COPD 患者中骨异常药物治疗的流行情况以及骨质疏松的临床决定因素。

方法

本横断面研究纳入了连续进入肺康复的 COPD 患者(n=554)。在进入肺康复之前,评估了病史、当前用药情况、吸烟状况、肺功能、骨矿物质密度、身体成分和其他临床特征。使用单变量和多变量多项逻辑回归分析来确定骨质疏松的相关因素。

主要结果

21%的患者患有骨质疏松症,41%的患者患有骨量减少症。骨质疏松症的药物治疗不足(82%的骨质疏松症患者未服用骨药物)。骨质疏松症的独立预测因素包括恶病质(OR:12.1;95%CI:4.5-32.7;p<0.001)、55 至 65 岁(OR:6.0;95%CI:2.2-16.3;p<0.001)和 65 岁以上(OR:11.7;95%CI:4.1-33.1;p<0.001)。超重(OR:0.1;95%CI:0.05-0.4;p=0.001)和肥胖(OR:0.78;95%CI:0.02-0.4;p=0.002)则有明显的保护作用。

结论

进入肺康复的大多数患有骨质疏松症的 COPD 患者未接受骨质疏松症的药物治疗。应筛查患有恶病质的 COPD 患者是否患有骨质疏松症,尤其是年龄超过 55 岁的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验